US 2015/0087681 A1Published application

Bendamustine HCL Stable Lyophilized Formulations

OwnerPranav Patel, Mahendra R. Patelinventors

Life of this patent

Estimating the term…

Abstract

The present invention provides a lyophilized bendamustine hydrochloride (HCL) pharmaceutical composition. The present invention further provides methods of producing the lyophilized bendamustine HCL composition from a composition including bendamustine HCL, mannitol, formic acid, and water. The pharmaceutical formulation can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.

Claims18

Dependent claims

A pharmaceutical composition comprising bendamustine or bendamustine hydrochloride, mannitol, formic acid, and water.

Dependencies are inferred from the claim text.

Facts

Application: 14/496,893Filed 25 Sep 2014
Priority: 25 Sep 2013
Published: 26 Mar 2015
Term ends: Not estimatedThe source records don’t support an estimate.

Classification4 codes

A61K 47/12
Containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides: carboxylic acids; Salts or anhydrides thereof
A61K 9/19
Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles: lyophilised , i.e.…
A61K 31/4184
1,3-Diazoles: condensed with carbocyclic rings, e.g. benzimidazoles
A61K
Medicines and medical preparations

Family

Application61/882,328Us provisional application · filed 25 Sep 2013
US 2015/0087681 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results